Dual-Targeted Fat Reduction: 48-Week Clinical Trial Validates 200% Enhanced Lipid Metabolism with Moringa-Citrus Synergy

Meta Description

Clinically proven moringa seed extract& citrus flavonoid blend boosts fat loss by 200% in human trials. Blue EyesBiotech’s patented dual-target technology for nutraceutical, cosmetic &pharmaceutical applications. Request samples.

Technical Abstract  

Blue Eyes Biotech unveils a revolutionarydual-target formulation (Patent No.: BE-MC2024) combining standardized moringaseed extract (10% isothiocyanates) and citrus flavonoids (50% hesperidin) thatelevated fat reduction by **200% versus placebo** in a 48-week randomizedclinical trial (n=180). Our proprietary **cold-jet milling technology**maximizes bioactive solubility, enabling simultaneous targeting of: 1)AMPK-mediated lipolysis activation and 2) PPAR-α induced fatty acid oxidation –a synergy confirmed via PET-CT scans showing visceral fat reduction of22.3% (p<0.001).  

Industrial-scale production leverages**high-pressure homogenization** to achieve 98% particle uniformity (<5μm),ensuring batch-to-batch consistency for global ODM partnerships. Costefficiency is demonstrated through **$125/kg bulk pricing** (500kg MOQ) – 30% below market averages – viaoptimized citrus waste valorization from sustainable sources. Cross-sectorapplications include: 1) Nutraceuticals: Enteric-coated capsules with 92%oral bioavailability; 2) **Cosmeceuticals**: Topical serums reducing adipocytesize by 41% in ex vivo models; 3) Functional Foods**: pH-stable powder forbeverage formulations.  

Certified under cGMP (21 CFR 111) and ISO9001**, the non-GMO formula meets FDA GRAS and EFSA Novel Food requirements.Procurement advantages:  

- Free 5kg trial batches** with clinicaldossier  

- Custom stability studies** (24-monthshelf-life data)  

- Scale-up support** from pilot to 20-tonbatches  

Request Clinical Trial Report**:[email protected] | www.blueeyes-bio.com